Equities

Actuate Therapeutics Inc

ACTU:NMQ

Actuate Therapeutics Inc

Actions
  • Price (USD)8.19
  • Today's Change0.19 / 2.37%
  • Shares traded4.56k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 20:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 202320232022
OPERATIONS
Net income(25)(20)
Depreciation/depletion----
Non-Cash items0.550.63
Cash taxes paid, supplemental00
Cash interest paid, supplemental00
Changes in working capital2.571.73
Total cash from operations(22)(18)
INVESTING
Capital expenditures----
Other investing and cash flow items, total----
Total cash from investing----
FINANCING
Financing cash flow items----
Total cash dividends paid----
Issuance (retirement) of stock, net4.1319
Issuance (retirement) of debt, net----
Total cash from financing4.1319
NET CHANGE IN CASH
Foreign exchange effects----
Net change in cash(17)1.46
Net cash-begin balance/reserved for future use2019
Net cash-end balance/reserved for future use2.9620
SUPPLEMENTAL INCOME
Depreciation, supplemental----
Cash interest paid, supplemental00
Cash taxes paid, supplemental00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.